### Comparison Table: Some Drugs for Maintenance Treatment of Opioid Use Disorder

<table>
<thead>
<tr>
<th>Drug</th>
<th>Some Available Formulations</th>
<th>Target Maintenance Dosage</th>
<th>Adverse Effects</th>
<th>Drug Interactions</th>
<th>Pregnancy/Lactation</th>
<th>Comments</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Buprenorphine</strong> – generic</td>
<td>2, 8 mg sublingual tabs; 74.2 mg subdermal implant; 100 mg/0.5 mL, 300 mg/1.5 mL prefilled syringes for subcutaneous injection</td>
<td>16 mg once/d; 4 implants for 6 mos; 100 mg once/mo (300 mg first 2 mos; increase to 300 mg once/mo if clinical response is inadequate)</td>
<td>▶ Sedation/respiratory depression (less than methadone), headache, abdominal pain, constipation, nausea, vomiting, insomnia, sweating&lt;br▶ Probuphine: implant-site pain, pruritus, and erythema; insertion and removal of drug-eluting implants has been associated with nerve injury and implant migration and extrusion&lt;br▶ Sublocade: injection-site reactions&lt;br▶ Bunavail: oral mucosal erythema</td>
<td>▶ Coadministration of benzodiazepines or other sedating drugs can be dangerous&lt;br▶ Inducers of CYP3A4 can reduce buprenorphine levels, and inhibitors of CYP3A4 can increase them&lt;br▶ Concurrent use of other serotonergic drugs can result in serotonin syndrome&lt;br▶ May interfere with analgesic activity of full opioid agonists</td>
<td>▶ Considered safe and effective for use in pregnant or breastfeeding women</td>
<td>▶ Buprenorphine is a schedule III controlled substance; can be prescribed in outpatient setting&lt;br▶ Generally considered the maintenance treatment of choice; similar in efficacy to methadone at higher doses&lt;br▶ Probuphine: approved for 6 or 12 months’ treatment in patients stabilized on ≤8 mg/d of buprenorphine; drug levels are similar to those with 8 mg/d of sublingual buprenorphine; REMS certification is required for prescribers&lt;br▶ Sublocade: approved for treatment of patients who have received transmucosal buprenorphine for ≥7 days with dose adjustment to 8–24 mg/d of buprenorphine sublingual tabs or equivalent; refrigerate during storage (discard if left at room temp for &gt;7 days); steady state buprenorphine levels with target dosage ~10% higher than those with 24 mg/d of sublingual tabs&lt;br▶ Cassipa: approved for use after induction and stabilization of the patient, and titration to a dose of 16 mg of buprenorphine using another product&lt;br▶ Efficacy of naloxone-containing formulations may be reduced in patients with severe hepatic impairment&lt;br▶ Bunavail 4.2/0.7 mg and Zubsolv 5.7/1.4 mg produce systemic buprenorphine levels equivalent to those seen with 8 mg of other buprenorphine formulations</td>
<td>▶ Considered safe and effective for use in pregnant or breastfeeding women</td>
</tr>
</tbody>
</table>

**Continued on next page**
<table>
<thead>
<tr>
<th>Drug</th>
<th>Some Available Formulations</th>
<th>Target Maintenance Dosage</th>
<th>Adverse Effects</th>
<th>Drug Interactions</th>
<th>Pregnancy/Lactation</th>
<th>Comments</th>
<th>Cost ($)</th>
</tr>
</thead>
</table>
| Methadone – generic | 5, 10 mg tabs; 5, 10 mg/5 mL oral solution; 10 mg/mL oral concentrate; 40 mg tabs for oral suspension | 80-120 mg once/d (some rapid metabolizers may require more frequent dosing) | ▶ Sedation/respiratory depression, constipation, lightheadedness, dizziness, sedation, nausea, vomiting, sweating, QT-interval prolongation and (rarely) arrhythmias such as torsades de pointes | ▶ Coadministration of benzodiazepines or other sedating drugs can be dangerous  
▷ Inducers of CYP3A4 or 2B6 can reduce methadone levels, and inhibitors of CYP3A4 or 2B6 can increase them  
▷ Concurrent use of other serotonergic drugs can result in serotonin syndrome  
▷ Concurrent use of other QT interval-prolonging drugs can cause arrhythmias such as torsades de pointes | ▶ Generally considered safe and effective for use in pregnant or breastfeeding women | ▶ Schedule II controlled substance; only available for treatment of opioid use disorder through opioid treatment programs with supervised dosing  
▷ Shown to reduce mortality in clinical trials; should be used when buprenorphine is unavailable or ineffective and in patients who would benefit from supervised dosing  
▷ Drug accumulates for 4-7 days during induction; respiratory depressant effect peaks later and lasts longer than analgesic effect  
▷ Federal law prohibits initial doses >30 mg or first daily doses >40 mg | $73.50  
Extra value: 850.80 |
| Dolophine (Roxane) | 5, 10 mg tabs | | | | | |
| Naltrexone – generic | 50 mg tabs | 50 mg once/d | ▶ Generally well tolerated; nasopharyngitis, insomnia, headache, nausea, and toothache are most commonly reported  
▶ Rarely: depressed mood/suicidality (cause and effect not established), hepatotoxicity (occurs frequently in opioid- and alcohol-dependent patients)  
▶ Vivitrol: injection-site reactions | ▶ Blocks effects of usual doses of opioids, including antiarrhythmics and antitussives  
▶ Can precipitate severe withdrawal in patients with physiological opioid dependence; patients should be free of dependence for ≥7 days before initiation  
▶ Discontinue 72 hours (oral formulation) or 30 days (IM formulation) before elective surgery | ▶ Data on safety and efficacy in pregnancy are limited; women at high risk for relapse can generally continue treatment  
▷ Women taking naltrexone should not breastfeed; the drug passes into breast milk to a clinically significant extent | ▶ Not a controlled substance  
▶ ER naltrexone is an alternative for highly motivated patients who do not have access to buprenorphine or methadone, or do not want to take an opioid, and for those who also have alcohol use disorder  
▶ Adherence is poor with oral naltrexone; it has generally only been effective in patients who were legally required to take the drug  
▶ Has not been shown to reduce mortality  
▶ Vivitrol: must be refrigerated; use within 7 days of removing from refrigerator (do not expose to temperatures >77°F) | 371.00  
Extra value: 1648.90  
7854.00 |
| Revia (Duramed) | 380 mg ER suspension for injection | 380 mg IM in alternating buttocks q4 wks or once/mo | | | | |
| extended-release microspheres – Vivitrol (Alkermes) | | | | | | |

N.A. = cost not yet available
3. To reduce the risk of drug diversion, the liquid formulation, diluted in colored water or juice, is generally used in treatment programs.